Immune Checkpoint Inhibitors (ICI) & Colorectal Cancer (CRC) (Mismatch Repair Deficiency (MMR-d) / DNA Mismatch Repair / Microsatellite Instability (MSI))

Immunotherapy with checkpoint inhibitors only plays a role in the 4%–6% of patients with MSIhigh tumors and even within this subpopulation, response rates can vary from 30% to 50%
Mendonça Gorgulho et al. 2021 J of Immunotherapy 44: 49-62

The key randomized clinical trials have been instrumental in demonstrating the efficacy of Immune Checkpoint Inhibitors (ICI), leading to FDA approval for their use in treating Colorectal Cancer (CRC) (Mismatch Repair Deficiency (MMR-d) / DNA Mismatch Repair / Microsatellite Instability (MSI)). These trials have shown significant clinical benefits, including improved survival rates and tumor response. The high-f…